Dr. Stanley Hazen
Thanks to a $750,000 grant from the Cleveland Foundation, Cleveland Clinic has established a chair for preventive cardiology.
Dr. Stanley Hazen — who holds several titles with the Clinic, including director for the Center for Cardiovascular Diagnostics and Prevention — has been chosen to hold the chair, according to a statement from the Clinic.
Hazen is no stranger to the medical innovation community. His research led to the invention of a biomarker test called CardioMPO that is the linchpin of a panel of heart inflammation tests for Cleveland HeartLab, one of the most promising companies in a stable of Cleveland Clinic spinoffs.
In addition to royalty payments from his HeartLab invention, Hazen receives royalties from Abbott Laboratories, Siemens and Frantz Biomarkers. He’s also been awarded stock by Pfizer for his work as a consultant with the drug developer.
Hazen’s specialty research interests include atherosclerosis, cardiac rehabilitation and cardiovascular risk evaluation, according to his bio on the Clinic’s site.
Reserve your seat now for MedCity CONVERGE, to be held July 9-10 in Philadelphia. Discover strategies, solutions and startups in healthcare innovation. Be a part of this gathering where the entire healthcare ecosystem converges.
By Brandon Glenn MedCity News
Brandon Glenn is the Ohio bureau chief for MedCity News.More posts by Author
As long as preventive cardiology is focused on medical technology including interventions and pharmaceuticals, we can be assured that treatment costs will continue to climb. At the same Cleveland Clinic where Dr. Hazen is now the preventive cardiology chair, is Dr. Caldwell Esselstyn who has "treated" and reversed coronary disease with a plant-based diet. I wonder if Dr. Hazen is even remotely considering research into this radical treatment...with funds coming from Abbott and Pfizer, not likely!